INDORAMIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H25N3O
Molecular Weight	347.4534
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4

InChI

InChIKey=JXZZEXZZKAWDSP-UHFFFAOYSA-N

InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)

HIDE SMILES / InChI

Molecular Formula	C22H25N3O
Molecular Weight	347.4534
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB08950

Indoramin is an alpha-1 selective antagonist of adrenergic receptor, sold under trade names Baratol and Doralese, and now available as a generic. It has no reflex tachycardia and direct myocardial depression action and is used to treat benign prostate hyperplasia (as 20 mg tablets) or reduce blood pressure (as 25 mg strength tablets). It was also investigated as a treatment of a migraine and congestive heart failure.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Alpha-1a adrenergic receptor 67 Target ID: CHEMBL229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9135028	Antagonist 2849	8.4 null [pKi]
Alpha-1b adrenergic receptor 45 Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9135028	Antagonist 2849	7.4 null [pKi]
Alpha-1d adrenergic receptor 37 Target ID: CHEMBL223 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9135028	Antagonist 2849	6.8 null [pKi]

Conditions

Condition	Modality	Highest Phase	Product
Benign prostatic hyperplasia 28 Sources: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con509423.pdf	Primary	Approved 8583	DORALESE Approved Use Indoramin 20 mg Tablets are used for a condition called ‘benign prostatic hyperplasia’ or BPH. The prostate is a gland found underneath the bladder in men. It surrounds the tube (called the urethra) which carries urine from the bladder to the outside of the body.
Hypertension 575 Sources: https://www.drugs.com/uk/indoramin-hydrochloride-25-mg-tablets-leaflet.html	Primary	Approved 8583	BARATOL Approved Use Baratol Tablets are used to reduce high blood pressure.
Congestive heart failure 54 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3543093	Primary	Not Provided 511	Unknown Approved Use Unknown
Migraine 107 Sources: https://www.ncbi.nlm.nih.gov/pubmed/49624	Primary	Not Provided 511	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
10.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328193/	37.5 mg single, oral dose: 37.5 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
15.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328193/	37.5 mg single, oral dose: 37.5 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
35.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3191938/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
37.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6499905/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
20.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6499905/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
18 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2897212/	37.5 mg 2 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
70.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2897212/	37.5 mg 2 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
76.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2897212/	37.5 mg 2 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
22.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3653231/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
65.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3653231/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
52.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2423791/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
51.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2423791/	25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
81.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328193/	37.5 mg single, oral dose: 37.5 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
73.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328193/	37.5 mg single, oral dose: 37.5 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
296 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3191938/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
697 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6499905/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
268 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6499905/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
81.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2897212/	37.5 mg 2 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
489 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2897212/	37.5 mg 2 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
524 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2897212/	37.5 mg 2 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
137 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3653231/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
127 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3653231/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
236 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3653231/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
246 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2423791/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
343 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2423791/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
349 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2423791/	25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
4.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328193/	37.5 mg single, oral dose: 37.5 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
3.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328193/	37.5 mg single, oral dose: 37.5 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3191938/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6499905/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
5.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6499905/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
4.22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2897212/	37.5 mg 2 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.67 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2897212/	37.5 mg 2 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.57 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2897212/	37.5 mg 2 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3653231/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.43 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3653231/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3653231/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2423791/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2423791/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	INDORAMIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2423791/	25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	INDORAMIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Analyte	Population
10% OTHER https://www.medicines.org.uk/emc/product/6666/smpc#PHARMACOKINETIC_PROPS	INDORAMIN plasma	Homo sapiens
14.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628508/	INDORAMIN plasma	Homo sapiens
8.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/788751/	INDORAMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
192 mg 1 times / day multiple, oral Highest studied dose Dose: 192 mg, 1 times / day Route: oral Route: multiple Dose: 192 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/780059/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/780059/	Disc. AE: Tiredness, Oedema... AEs leading to discontinuation/dose reduction: Tiredness (grade 3, 5.3%) Oedema (10.6%) Weight gain (10.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/780059/
122 mg 1 times / day multiple, oral Studied dose Dose: 122 mg, 1 times / day Route: oral Route: multiple Dose: 122 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/	Other AEs: Drowsiness, Dizziness... Other AEs: Drowsiness (29%) Dizziness (10%) Dry mouth (7%) Fatigue (14%) Depression (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/

AEs

AE	Significance	Dose	Population
Oedema	10.6% Disc. AE	192 mg 1 times / day multiple, oral Highest studied dose Dose: 192 mg, 1 times / day Route: oral Route: multiple Dose: 192 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/780059/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/780059/
Weight gain	10.6% Disc. AE	192 mg 1 times / day multiple, oral Highest studied dose Dose: 192 mg, 1 times / day Route: oral Route: multiple Dose: 192 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/780059/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/780059/
Tiredness	grade 3, 5.3% Disc. AE	192 mg 1 times / day multiple, oral Highest studied dose Dose: 192 mg, 1 times / day Route: oral Route: multiple Dose: 192 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/780059/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/780059/
Dizziness	10%	122 mg 1 times / day multiple, oral Studied dose Dose: 122 mg, 1 times / day Route: oral Route: multiple Dose: 122 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/
Fatigue	14%	122 mg 1 times / day multiple, oral Studied dose Dose: 122 mg, 1 times / day Route: oral Route: multiple Dose: 122 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/
Depression	2%	122 mg 1 times / day multiple, oral Studied dose Dose: 122 mg, 1 times / day Route: oral Route: multiple Dose: 122 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/
Drowsiness	29%	122 mg 1 times / day multiple, oral Studied dose Dose: 122 mg, 1 times / day Route: oral Route: multiple Dose: 122 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/
Dry mouth	7%	122 mg 1 times / day multiple, oral Studied dose Dose: 122 mg, 1 times / day Route: oral Route: multiple Dose: 122 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2423807/

PubMed

Title	Date	PubMed
[Acute bilateral angle-closure glaucoma induced by topiramate: contribution of Visante OCT].	2010-05	20434235
Torsade de pointes: a severe and unknown adverse effect in indoramin self-poisoning.	2009-04-03	18191476
Alpha antagonists and intraoperative floppy iris syndrome: A spectrum.	2008-12	19668424
Optimizing prophylactic treatment of migraine: Subtypes and patient matching.	2008-10	19209286
Recent advances in the pharmacotherapy of chronic anal fissure: an update.	2008-07	18658016
Pharmacological causes of hyperprolactinemia.	2007-10	18473017
Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates.	2007-08	17629959
Prokinetic effect of alpha-adrenergic antagonist, and beta-adrenergic antagonist on gall-bladder motility in humans with gall-stone disease.	2007-07	17556905
Non surgical therapy for anal fissure.	2006-10-18	17054170
Increased cholinergic contractions of jejunal smooth muscle caused by a high cholesterol diet are prevented by the 5-HT4 agonist--tegaserod.	2006-02-23	16504074
Pharmacological advancements in the treatment of chronic anal fissure.	2005-11	16259578
Current treatment options for fissure-in-ano.	2005-05-11	15881700
Khat chewing and arterial blood pressure. A randomized controlled clinical trial of alpha-1 and selective beta-1 adrenoceptor blockade.	2005-04	15900355
5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.	2004-05	15082205
Use of alpha-blockers and the risk of hip/femur fractures.	2003-12	14641795
Effect of cyproterone acetate on alpha1-adrenoceptor subtypes in rat vas deferens.	2003-11	14576912
[Drug-induced hyperprolactinemia: a case-non-case study from the national pharmacovigilance database].	2003-08-29	12942857
Functional characterisation of alpha(1)-adrenoceptors in denervated rat vas deferens.	2003-07	12845422
Drug-related hyperprolactinemia.	2003-02	12602384
Prokinetic effect of indoramin, an alpha-adrenergic antagonist, on human gall-bladder.	2002-10	12269974
The medical and surgical management of chronic anal fissure.	2002-09	12469422
The use of alpha-adrenoceptor antagonists in lower urinary tract disease.	2002-02	11829730
[Migraine: a disease, not a symptom].	2002-01-01	11852766
A double-blind randomized placebo-controlled trial of oral indoramin to treat chronic anal fissure.	2001-05	12790983
Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies.	1999-04-16	10334511
Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.	1997-07	9249248
Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy.	1995-01-16	7536677
The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype.	1994-04	8183249
Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin.	1986-02	3955309
A double-blind comparison of indoramin and propranolol in the treatment of moderate to severe essential hypertension.	1983	6365463

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is one tablet (20 mg) twice a day. The tablet should be swallowed with water. Some elderly patients may need just one tablet at night. The patient’s doctor may increase their dose to a maximum total daily dose of 100 mg. The patient must not take more than their doctor has recommended.

Route of Administration: Oral

In Vitro Use Guide

Binding of indoramin to alpha1 receptors was studied using rat cerebral cortex membranes with [3H]prazosin to label alpha1 adrenoreceptors. Indoramin displaces prozasin with IC50 pKi of 7.61.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:32:49 GMT 2025` Edited by `admin` on `Mon Mar 31 18:32:49 GMT 2025`
Record UNII	0Z802HMY7H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

INDORAMIN

Official Name

English

WY-21901

Preferred Name

English

Indoramin [WHO-DD]

Common Name

English

INDORAMIN [USAN]

Common Name

English

indoramin [INN]

Common Name

English

INDORAMIN [MI]

Common Name

English

N-[1-(2-Indol-3-ylethyl)-4-piperidyl]benzamide

Systematic Name

English

BENZAMIDE, N-(1-(2-(1H-INDOL-3-YL)ETHYL)-4-PIPERIDINYL)-

Systematic Name

English

WY 21901

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C29713